Abstract

Simple SummaryBased on literature evidence, it is difficult to conclude the advantages and safety of IMPT in patients with NPC. We performed propensity score matching analysis of patients treated with IMPT and VMAT by the same group of physicians within the same institute. Finally, we observed that IMPT reduced the requirement of nasogastric tube insertion and body weight loss during treatment, and the oncologic outcomes were potentially better than that of VMAT. However, IMPT increased the rate of grade III radiation dermatitis. Our current data indicate that IMPT is safe and beneficial as a frontline therapy for patients with NPC.(1) Background: We compared the outcomes of patients with nasopharyngeal carcinoma treated with IMPT and VMAT. (2) Methods: We performed a retrospective propensity score matching analysis (1:1) of patients treated with IMPT (years: 2016–2018) and VMAT (2014–2018). Survival was estimated using the Kaplan–Meier method. Multivariate Cox proportional hazards regression analysis was used to identify the independent predictors of survival. Binary toxicity endpoint analyses were performed using a Cox model and logistic regression. (3) Results: Eighty patients who received IMPT and VMAT were included. The median follow-up time was 24.1 months in the IMPT group. Progression-free survival (PFS) and overall survival (OS) were not statistically different between the two groups but potentially better in IMPT group. In multivariate analysis, advanced N-stage and body weight loss (BWL; >7%) during radiotherapy were associated with decreased PFS. The IMPT group had significantly less requirement for nasogastric (NG) tube placement and BWL during treatment. The mean oral cavity dose was the only predictive factor in stepwise regression analysis, and IMPT required a significantly lower mean dose. However, IMPT increased the grade 3 radiation dermatitis. (4) Conclusions: IMPT is associated with reduced rates of NG tube insertion and BWL through reducing oral mean dose, potentially producing better oncologic outcomes.

Highlights

  • Nasopharyngeal carcinoma (NPC) affected an estimated 130,000 patients worldwide in2018

  • Patients treated with Intensity-modulated proton therapy (IMPT) were propensity score-matched at a 1:1 ratio with those receiving Volumetric modulated arc therapy (VMAT) based on factors that influenced treatment volumes and expected acute toxicity during RT, with the nearest neighbor method without replacement

  • For patients treated with VMAT, a 3 or 5 mm planning target volume (PTV) expansion was added to the CTV volumes depending on whether they received image-guided RT

Read more

Summary

Introduction

Nasopharyngeal carcinoma (NPC) affected an estimated 130,000 patients worldwide in. 2018. Proton beam therapy is an attractive treatment strategy that decreases unnecessary dose to normal tissues. MFO-IMPT can be used to design and deliver high conformal and complex dose distributions to the target, while sparing the organs at risk (OARs). This simultaneous integrated boost treatment plan can be readily created with IMPT, similar to IMRT [12]. We investigated the outcomes of patients with NPC treated using IMPT from an endemic area, and analyzed whether they showed satisfactory oncologic outcomes and reduced morbidity when compared to propensity score-matched controls treated with VMAT

Patient Selection
Radiotherapy and Chemotherapy
Statistical Analysis
Patient and Tumor Characteristics
Oncological Outcome
Common Acute AEs
Discussion
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call